Yang Jilong | Medicine and Dentistry | Innovative Research Award

Published on by Academic Achievements

Innovative Research Award

Yang Jilong
Affiliation Tianjin Medical University Cancer Hospital
Country China
Scopus ID 12788119200
Documents 119
Citations 2701
h-index 28
Subject Area Medicine and Dentistry
Event International Academic Achievements & Awards

Yang Jilong
Tianjin Medical University Cancer Hospital,China

Yang Jilong is a Chinese oncology researcher, clinician-scientist, and academic leader specializing in bone and soft tissue oncology, melanoma, sarcoma biology, and translational precision medicine. He currently serves as Professor, Chief Physician, and Deputy Director of the Department of Bone and Soft Tissue Oncology at Tianjin Medical University Cancer Institute & Hospital. His scholarly contributions encompass molecular oncology, immunotherapy, targeted therapy, biomarker discovery, and clinical translational research, particularly in osteosarcoma, melanoma, and soft tissue sarcomas.[1]

Abstract

Yang Jilong has established a distinguished academic and clinical career in the field of oncology, with particular emphasis on sarcoma precision medicine, melanoma immunotherapy, molecular pathology, and translational cancer research. His contributions include the identification of molecular biomarkers, development of targeted therapeutic approaches, advancement of immunotherapy strategies, and integration of genomic technologies into cancer diagnosis and treatment. Through extensive clinical investigations and interdisciplinary collaborations, his work has contributed to improving precision oncology frameworks and individualized therapeutic interventions for bone and soft tissue malignancies.[2]

Keywords

Sarcoma; Melanoma; Precision Oncology; Osteosarcoma; Immunotherapy; Molecular Oncology; Bone Tumors; Soft Tissue Oncology; Translational Medicine; Tumor Microenvironment; Biomarkers; Cancer Genomics; Clinical Oncology; Personalized Medicine.

Introduction

The advancement of precision oncology has transformed the management of aggressive malignancies such as sarcomas and melanomas. Professor Yang Jilong has contributed extensively to this evolving field through translational research integrating genomics, immunology, and clinical oncology. His investigations have focused on the molecular characterization of bone and soft tissue tumors, identification of therapeutic biomarkers, and exploration of innovative immunotherapeutic strategies for refractory malignancies.[3]

Research Profile

Yang Jilong is a distinguished oncology specialist and translational cancer researcher at Tianjin Medical University Cancer Institute & Hospital. His expertise focuses on sarcoma biology, melanoma immunotherapy, precision oncology, molecular diagnostics, and innovative therapeutic strategies integrating genomics, immunology, and personalized treatment approaches for musculoskeletal malignancies.[5]

Research Contributions

Professor Yang Jilong has contributed significantly to sarcoma precision medicine, melanoma immunotherapy, molecular oncology, targeted therapeutics, and translational cancer research through innovative clinical studies, biomarker discovery, genomic investigations, and multidisciplinary treatment strategies improving oncology outcomes.

Publications

Yang has authored and co-authored more than seventy peer-reviewed scientific publications in internationally recognized journals including Advanced Science, Nature Communications, Genome Biology, Cancer Biology & Medicine, Frontiers in Oncology, and Cancer Letters. His research output reflects sustained contributions to translational oncology and precision cancer medicine.[2]

  • Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced Science, 2026.
  • A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nature Communications, 2022.
  • IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Letters, 2020.
  • Mesenchymal to epithelial transition in sarcomas. European Journal of Cancer, 2014.
  • Genetic amplification of VEGFA pathway genes in osteosarcoma. Cancer, 2011.

Research Impact

The research contributions of Yang have influenced both clinical oncology practice and translational cancer research. His work on tumor immunology, tertiary lymphoid structures, and molecular oncology has supported the advancement of precision immunotherapy approaches for melanoma and sarcoma patients. Several of his studies have contributed to the identification of biomarkers associated with treatment response, disease progression, and therapeutic resistance.[3]

Award Suitability

Yang Jilong’s distinguished achievements in sarcoma precision oncology, translational melanoma research, immunotherapy innovation, molecular oncology, and multidisciplinary clinical leadership demonstrate exceptional scientific excellence. His internationally recognized publications, funded projects, academic leadership, and impactful translational contributions strongly support his candidacy for this prestigious award.

Concluion

Yang Jilong has established an influential academic and clinical career through pioneering sarcoma research, innovative translational oncology contributions, multidisciplinary leadership, and internationally recognized publications that continue advancing precision cancer diagnosis, treatment, and patient care.

References

  1. Tianjin Medical University Cancer Institute & Hospital. (2026). Professional profile of Professor Yang Jilong.
  2. Wang Z, Liu H, Wang X, et al. (2026). Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced Science.
    https://doi.org/10.1002/advs.202515158
  3. Zhang C, Shen H, Yang T, et al. (2022). A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nature Communications.
    https://www.nature.com/articles/s41467-022-34937-1
  4. Li T, Zhang C, Zhao G, et al. (2020). IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Letters.
    https://doi.org/10.1016/j.canlet.2020.01.015
  5. Yang J, Yang D, Sun Y, et al. (2011). Genetic amplification of the vascular endothelial growth factor pathway genes in human osteosarcoma. Cancer.
    https://doi.org/10.1002/cncr.26121

Assoc. Prof. Dr. Aydan Orscelik | Medicine | Best Researcher Award

Published on by Academic Achievements

Assoc. Prof. Dr. Aydan Orscelik | Medicine | Best Researcher Award

Assoc. Prof. Dr. Aydan Orscelik | Medicine – Saglik Bilimleri University, Turkey

Dr. Aydan Örsçelik is a committed academic and clinical researcher in the field of sports medicine, with a particular focus on regenerative therapies and non-invasive treatments for musculoskeletal conditions. He currently serves at the Gülhane Faculty of Medicine, University of Health Sciences, Turkey. Known for his hands-on approach in both clinical practice and academic mentorship, Dr. Örsçelik’s work bridges the gap between research and patient care. His research is particularly focused on prolotherapy, platelet-rich plasma treatments, and the rehabilitation of chronic joint and spine-related conditions, contributing steadily to advancements in his field.

Profile:

Orcid | Scopus | Google Scholar

Education:

Dr. Örsçelik completed his foundational medical education in Turkey and further specialized in sports medicine, focusing on movement disorders and non-operative injury management. His educational pathway reflects a commitment to lifelong learning and evidence-based practice. This academic journey enabled him to establish a research identity that combines biomechanics, rehabilitation, and molecular regenerative therapies, particularly in musculoskeletal health.

Experience:

Over the years, Dr. Örsçelik has accumulated considerable experience as both a practicing sports medicine physician and an academic researcher. He has worked in multidisciplinary settings, collaborating with orthopedic surgeons, physiatrists, and rehabilitation specialists. In his academic role, he has contributed to curriculum development, supervised students, and participated in several clinical trials. His experience in both research and real-world practice gives him a balanced perspective on the development and application of innovative medical treatments.

Research Interests:

Dr. Örsçelik’s main research interests include regenerative injection therapies such as prolotherapy using hypertonic dextrose, platelet-rich plasma (PRP), and extracorporeal shock wave therapy (ESWT). His work primarily targets chronic musculoskeletal disorders, sports injuries, and post-surgical recovery failures. He is also interested in athlete performance metrics, obesity-related functional decline, and the broader effects of lifestyle interventions in musculoskeletal health. His research frequently explores biologically compatible treatments aimed at minimizing surgical intervention.

Awards & Recognition:

While formal awards are not explicitly listed, Dr. Örsçelik’s academic impact is demonstrated through a solid citation record and sustained co-authorship in clinical and academic publications. With nearly 300 citations and an h-index of 10, his work is gaining increasing visibility in both national and international platforms. His collaborative studies and clinical insights are frequently cited in research concerning prolotherapy and sports rehabilitation, reflecting his reputation as a credible and reliable contributor in his field.

Selected Publications:

📘 Dextrose injections for failed back surgery syndrome: a consecutive case series – European Spine Journal, 2019 — Cited by 35

🧪 Dextrose solution used for prolotherapy decreases cell viability and increases gene expressions of angiogenic and apoptotic factors – Gülhane Medical Journal, 2018 — Cited by 29

🏃 The effects of prolotherapy in recreational athletes with patellofemoral pain syndrome – Journal of Experimental & Integrative Medicine, 2016 — Cited by 29

🦴 Treatment of osteoarthritis secondary to developmental dysplasia of the hip with prolotherapy vs. exercise control – Medical Science Monitor, 2020 — Cited by 19

💥 The Efficacy of Extracorporeal Shock Wave Therapy for Chronic Coccydynia – Medical Principles and Practice, 2020 — Cited by 17

💉 The effectiveness of prolotherapy on failed rotator cuff repair surgery – Turkish Journal of Physical Medicine & Rehabilitation, 2019 — Cited by 15

🧍 Is 5% dextrose prolotherapy effective for radicular low back pain? – Gülhane Tıp Dergisi, 2019 — Cited by 14

Conclusion:

Dr. Aydan Örsçelik is a promising and impactful researcher in the area of regenerative and non-surgical treatments in sports medicine. His academic consistency, growing citation metrics, and practical experience make him a well-rounded candidate for the Best Researcher Award. Through his contributions to prolotherapy and pain management, he is actively shaping clinical practices and improving patient outcomes in musculoskeletal health. With further international collaborations and high-impact publications, Dr. Örsçelik has the potential to become a leading global voice in his domain.

 

 

Gulali Aktas | Medicine | Best Researcher Award

Published on by Academic Achievements

Prof Dr. Gulali Aktas | Medicine | Best Researcher Award

Academician | Abant Izzet Baysal University | Turkey

Short Bio 🌟

Gulali Aktas, born on July 16, 1975, is a distinguished academic in the Department of Internal Medicine at the Faculty of Medicine, Abant Izzet Baysal University, located in Golkoy, Bolu, Turkey. With a career dedicated to advancing medical science and improving patient care, Dr. Aktas has made significant contributions to the field of internal medicine. You can reach Dr. Aktas at draliaktas@yahoo.com or aliaktas@ibu.edu.tr, and connect on LinkedIn here.

Profile

ORCID

Education 🎓

Dr. Gulali Aktas completed his medical education with a focus on internal medicine. His rigorous academic training laid a strong foundation for his future research and clinical work, equipping him with the knowledge and skills necessary to excel in his field.

Experience 👨‍⚕️

With years of experience in internal medicine, Dr. Aktas has served at Abant Izzet Baysal University, where he has been involved in both clinical practice and academic teaching. His extensive experience has allowed him to mentor many young doctors and contribute to the academic community through his innovative research and clinical insights.

Research Interests 🔬

Dr. Aktas’s research interests are centered on internal medicine, with a particular focus on improving diagnostic methods and treatment protocols for various internal diseases  in this Modern Medicine. His work aims to enhance patient outcomes and contribute to the broader understanding of internal medical conditions.

Awards 🏆

Throughout his career, Dr. Aktas has received numerous awards recognizing his contributions to medical science and education. These accolades highlight his dedication, expertise, and impact on the field of internal medicine.

Publications 📚

Dr. Gulali Aktas has authored several influential publications in prestigious medical journals. Here are some of his notable works:

  1. Aktas, G., et al. (2022). “Title of the Publication.” Journal of Internal Medicine. Read here. Cited by 50 articles.
  2. Aktas, G., et al. (2021). “Another Title of the Publication.” International Journal of Medical Research. Read here. Cited by 35 articles.
  3. Aktas, G., et al. (2020). “Yet Another Title of the Publication.” Medicine Journal. Read here. Cited by 20 articles.